[go: up one dir, main page]

ES2184800T3 - Uso de agentes anti-vegf en el tratamiento de la endometriosis. - Google Patents

Uso de agentes anti-vegf en el tratamiento de la endometriosis.

Info

Publication number
ES2184800T3
ES2184800T3 ES95919578T ES95919578T ES2184800T3 ES 2184800 T3 ES2184800 T3 ES 2184800T3 ES 95919578 T ES95919578 T ES 95919578T ES 95919578 T ES95919578 T ES 95919578T ES 2184800 T3 ES2184800 T3 ES 2184800T3
Authority
ES
Spain
Prior art keywords
endometriosis
treatment
pct
date
vegf agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95919578T
Other languages
English (en)
Inventor
David Stephen Charnock-Jones
John Mclaren
Andrew Prentice
Stephen Kevin Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metris Therapeutics Ltd
Original Assignee
Metris Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metris Therapeutics Ltd filed Critical Metris Therapeutics Ltd
Application granted granted Critical
Publication of ES2184800T3 publication Critical patent/ES2184800T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE MUESTRA : UNA COMPOSICION PARA USAR EN EL TRATAMIENTO DE LA ENDOMETRIOSIS, QUE INCLUYE UN AGENTE CAPAZ DE INTERFERIR LA PRODUCCION Y/O ACTIVIDAD DE VEGF, Y UNA SUSTANCIA DE TRANSPORTE ACEPTABLE FISIOLOGICAMENTE; UNA COMPOSICION PARA EL TRATAMIENTO DE LA ENDOMETRIOSIS QUE INCLUYE UN AGENTE PARA INHIBIR LA ACTIVACION Y/O RECLUTAMIENTO DE MACROFAGOS PERITONEALES, Y UN TRANSPORTE ACEPTABLE FISIOLOGICAMENTE, Y METODOS PARA ELABORAR LAS COMPOSICIONES Y SU USO EN EL TRATAMIENTO DE LA ENDOMETRIOSIS.
ES95919578T 1994-05-26 1995-05-26 Uso de agentes anti-vegf en el tratamiento de la endometriosis. Expired - Lifetime ES2184800T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9410533A GB9410533D0 (en) 1994-05-26 1994-05-26 In situ hybridisation and immuno-Chemical localisation of a growth factor

Publications (1)

Publication Number Publication Date
ES2184800T3 true ES2184800T3 (es) 2003-04-16

Family

ID=10755736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95919578T Expired - Lifetime ES2184800T3 (es) 1994-05-26 1995-05-26 Uso de agentes anti-vegf en el tratamiento de la endometriosis.

Country Status (11)

Country Link
US (1) US6121230A (es)
EP (1) EP0771192B1 (es)
JP (1) JPH10505321A (es)
AT (1) ATE222488T1 (es)
AU (1) AU692874B2 (es)
CA (1) CA2191070A1 (es)
DE (1) DE69527847T2 (es)
ES (1) ES2184800T3 (es)
GB (1) GB9410533D0 (es)
NZ (1) NZ285833A (es)
WO (1) WO1995032708A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005293A2 (en) 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
ATE296117T1 (de) 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
US6753138B1 (en) 1998-06-04 2004-06-22 Reprogen, Inc. Use of prothymosin in the diagnosis and treatment of endometriosis
JP2002517209A (ja) * 1998-06-04 2002-06-18 リプロジェン， インコーポレイテッド 子宮内膜症の診断および処置におけるプロサイモシンの使用
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
CN101073668A (zh) 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
EP1399484B1 (en) * 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2455194A1 (en) * 2001-08-01 2003-02-13 University Of Bristol Vascular endothelial growth factor isoform having anti-angiogenic activity
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
DE10229379A1 (de) * 2002-06-26 2004-01-29 Schering Ag EG-VEGF Rezeptor Antagonisten
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
SI1517921T1 (sl) * 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1578801A2 (en) * 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
BRPI0408749B1 (pt) * 2003-03-28 2016-10-04 Regeneron Pharma uso do antagonista de vegf vegfr1r2-fc delta c1(a)
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050214280A1 (en) * 2004-03-02 2005-09-29 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
WO2006087722A1 (en) * 2005-02-17 2006-08-24 Hadasit Medical Research Services And Development Ltd. Bisphosphonates for treating endometriosis
WO2007063308A2 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
CN103638522A (zh) * 2006-01-18 2014-03-19 通用医疗公司 增强淋巴功能的方法
BRPI0812398A2 (pt) 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
WO2011073521A1 (en) 2009-12-15 2011-06-23 Petri Salven Methods for enriching adult-derived endothelial progenitor cells and uses thereof
EP3696195B1 (en) 2010-07-23 2024-02-14 Trustees of Boston University Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
US20130022551A1 (en) 2011-07-22 2013-01-24 Trustees Of Boston University DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
MA40354A (fr) 2014-07-18 2017-05-24 Sanofi Sa Procédé permettant de prédire le résultat d'un traitement avec de l'aflibercept d'un patient suspecté de souffrir d'un cancer
WO2017015334A1 (en) * 2015-07-21 2017-01-26 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP1167384B1 (en) * 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
JP3734262B2 (ja) * 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤

Also Published As

Publication number Publication date
JPH10505321A (ja) 1998-05-26
EP0771192B1 (en) 2002-08-21
ATE222488T1 (de) 2002-09-15
EP0771192A1 (en) 1997-05-07
CA2191070A1 (en) 1995-12-07
DE69527847D1 (de) 2002-09-26
WO1995032708A1 (en) 1995-12-07
AU2535395A (en) 1995-12-21
NZ285833A (en) 1999-09-29
AU692874B2 (en) 1998-06-18
US6121230A (en) 2000-09-19
GB9410533D0 (en) 1994-07-13
DE69527847T2 (de) 2003-04-30

Similar Documents

Publication Publication Date Title
ES2184800T3 (es) Uso de agentes anti-vegf en el tratamiento de la endometriosis.
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
WO2002041837A3 (en) Treatment of mucositis
NO20054249L (no) Anvendelse av komposisjon for fremstilling av et farmasoytisk preparat for forhindring eller behandling av kloe hos en pasient
HU9503826D0 (en) Heterocycles useful as neurokinin antagonists
BR9913800A (pt) Método para tratar glaucoma, e, composição para tratar glaucoma
DE69627147D1 (de) Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
DE60040753D1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
DE69932510D1 (de) Vaskularisierungsinhibitoren
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
ATE218868T1 (de) Hustenhemmende, theobromine enthaltende zusammensetzungen
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
RS49599B (sr) Upotreba inhibitora h+, k+-atp-aze i glukokortikoida i farmaceutska formulacija
SE9802937D0 (sv) Novel compounds
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
ES2156215T3 (es) Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.